Our previous study [24] showed that low-dose or short-term use of G-CSF in patients with multiple myeloma was not associated with the incidence or severity of CRS or NEs, and G-CSF administration did not affect the efficacy of CAR T-cell therapy. Here, CSF3 is linked to plasma cell myeloma.